Accepted for Publication: October 15, 2021.
Published Online: November 23, 2021. doi:10.1001/jamaoncol.2021.6764
Corresponding Author: Albert Grinshpun, MD, MSc, Breast Oncology Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (albert_grinshpun@dfci.harvard.edu).
Author Contributions: Drs Rottenberg and Grinshpun had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Rottenberg and Grinshpun served as co–first authors.
Concept and design: Grinshpun, Kadouri.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Rottenberg, Grinshpun, Oiknine Djian, Kadouri.
Critical revision of the manuscript for important intellectual content: Grinshpun, Ben-Dov, Wolf, Kadouri.
Statistical analysis: Ben-Dov.
Administrative, technical, or material support: Grinshpun, Oiknine Djian, Wolf, Kadouri.
Supervision: Rottenberg, Kadouri.
Conflict of Interest Disclosures: Dr Grinshpun reported support from the Israel Science Foundation (grant 3020/20) and the 2020 Conquer Cancer Israel Cancer Research Fund Career Development Award. Dr Kadouri reported support from Eli Lilly outside the submitted work. No other disclosures were reported.
Additional Contributions: We would like to thank all of the patients in this study as well as Miri Shapira from the Sharett Institute of Oncology at Hadassah Medical Center for her kind assistance in samples collection. Ms Shapira was compensated for her contributions.
3.Grinshpun
A , Rottenberg
Y , Ben-Dov
IZ , Djian
E , Wolf
DG , Kadouri
L . Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment.
ESMO Open. 2021;6(6):100283. doi:
10.1016/j.esmoop.2021.100283PubMedGoogle Scholar